New findings on the effects of incretin analogs

A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy and the effects of discontinuation. Interesting new findings were also published on the GLP-1 RA semaglutide. McGowan et al. looked at the effects in obese patients with prediabetes, while Deanfield et al. investigated possible cardioprotective effects in obesity and comorbid atherosclerotic cardiovascular disease.